In June 2025, the FDA approved Lenacapavir, a twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP), following striking trial results showing near-perfect efficacy. This long-acting injectable represents a game-changing innovation, promising to transform HIV prevention by reducing pill burden, stigma, and adherence challenges for individuals at high risk of infection. However, despite its potential, Lenacapavir is being launched into a system where access to life-saving treatments remains deeply unequal. Currently priced at over 28 000 annually in the United States, Lenacapavir may remain out of reach for millions in low- and middle-income countries (LMICs) unless global action is taken. Although, Gilead Sciences has entered voluntary licensing agreements, historical patterns suggest that production, registration, and distribution delays may once again exclude the most vulnerable. Without enforceable commitments, voluntary mechanisms risk perpetuating the same global health divides that once delayed antiretroviral access across sub-Saharan Africa. This perspective argues that Lenacapavir’s success must not be judged by regulatory approval alone, but by the speed and scale of equitable implementation. Unless governments, funders, and civil society act now, this biomedical triumph could widen the very disparities it seeks to overcome. The breakthrough and advancement is real but so is the risk of leaving millions behind.
Goshen David Miteu (Wed,) studied this question.